Ancient chinese herbal formula tested for rare muscle disease
NCT ID NCT07472777
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study looked at whether a modified traditional Chinese herbal formula, Guilu Erxian Glue, can help people with myasthenia gravis (a disease causing muscle weakness). Researchers reviewed medical records of 231 patients who took the herbal formula alongside standard Western medicine. They measured how many patients had a relapse and how quickly they could reduce their regular medications.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- Modified Guilu Erxian Glue (traditional Chinese herbal formula)
- What this could lead to
- If effective, this herbal formula could help control myasthenia gravis symptoms and reduce recurrence when added to standard Western medicine.
- What could go wrong
- This is a retrospective study, not a controlled trial, so results may be biased. The herbal formula's benefits are uncertain and may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS (MG) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Henan University of Chinese Medicine
Zhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking daily life unlock myasthenia gravis mysteries?
- Hidden toll of myasthenia gravis: study probes sexual and bladder problems often overlooked
- Engineered immune cells take aim at autoimmune diseases
- New drug aims to ease daily struggles of myasthenia gravis
- New drug MTM-H-001 targets B-Cell autoimmune diseases in early trial
- New study aims to uncover hidden clues in myasthenia gravis